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Skin prick testing is an essential test procedure to confirm sensitization in IgE-mediated allergic disease in subjects
with rhinoconjunctivitis, asthma, urticaria, anapylaxis, atopic eczema and food and drug allergy. This manuscript
reviews the available evidence including Medline and Embase searches, abstracts of international allergy meetings
and position papers from the world allergy literature. The recommended method of prick testing includes the
appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 – 20
minutes of application, with a positive result defined as a wheal ≥3 mm diameter. A standard prick test panel for
Europe for inhalants is proposed and includes hazel (Corylus avellana), alder (Alnus incana), birch (Betula alba), plane
(Platanus vulgaris), cypress (Cupressus sempervirens), grass mix (Poa pratensis, Dactilis glomerata, Lolium perenne,
Phleum pratense, Festuca pratensis, Helictotrichon pretense), Olive (Olea europaea), mugwort (Artemisia vulgaris),
ragweed (Ambrosia artemisiifolia), Alternaria alternata (tenuis), Cladosporium herbarum, Aspergillus fumigatus,
Parietaria, cat, dog, Dermatophagoides pteronyssinus, Dermatophagoides farinae, and cockroach (Blatella germanica).
Standardization of the skin test procedures and standard panels for different geographic locations are encouraged
worldwide to permit better comparisons for diagnostic, clinical and research purposes.
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IgE-mediated allergic disease in patients with rhinocon-
junctivitis, asthma, urticaria, anapylaxis, atopic eczema
and suspected food and drug allergy. It provides evi-
dence for sensitization and can help to confirm the diag-
nosis of a suspected type I allergy. It is minimally
invasive, inexpensive, results are immediately available
and when carried out by trained health professionals,
reproducible. Since the first publication about SPT by
Helmtraud Ebruster in 1959 [1], who extensively
researched this diagnostic test, it has been used as a pri-
mary diagnostic tool to detect type I hypersensitivity
reactions. Although the principle of SPT still largely
resembles the original methods described, a wide array
of interpretations and modifications has led to dimin-
ished comparability when SPT results are reported. In* Correspondence: lucie.heinzerling@uk-erlangen.de
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distribution, and reproduction in any mediumaddition, the different kind of extracts used in various
countries makes comparison of data difficult.
The Global Allergy and Asthma European Network
(GA2LEN) is a network of research investigators formed
to augment the cooperation of allergy and asthma re-
search throughout Europe. The purpose of the GA2LEN
quality management is to standardize procedures used
to diagnose and treat allergic diseases. A survey was
conducted to assess SPT practices at the different par-
ticipating centres at the debut of the program. Although
there were similarities in technique for SPT, e.g., the use
of positive and negative controls and requesting infor-
mation from the patient about medications that could
interfere with test results, there were also striking differ-
ences [2]. These investigators realized that standardization
of SPT procedures is desirable so that findings from
clinical practice and research become more comparable.
Therefore, a GA2LEN protocol was developed using a
common panel of inhalant allergens (Table 1) and a stand-
ard operating procedure to perform and appropriately
interpret SPT results based on published practicetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Standard prick test panel for inhalant allergens
Allergen/control
Histamindihydrochloride 0,1
% (positive control)
NaCl 0.9% (negative
control)
Hazel Corylus avellana
Alder Alnus incana
Birch Betula alba
Plane Platanus vulgaris
Cypress Cupressus sempervirens
Grass mix smooth meadow grass/Poa pratensis,
cock’s foot grass/Dactilis glomerata,
perennial rye grass/Lolium perenne,
timothy grass/Phleum pratense, meadow
fescue/Festuca pratensis, meadow oat
grass/Helictotrichon pretense
Olive Olea europaea
Mugwort Artemisia vulgaris
Ragweed Ambrosia artemisiifolia
Alternaria Alternaria alternata (tenuis)
Cladosporium Cladosporium herbarum
Aspergillus Aspergillus fumigatus
Parietaria Parietaria
Cat
Dog
Dermatophagoides
pteronyssinus
Dermatophagoides farinae
Blatella Blatella germanica
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Immunology (EAACI) Position Paper, the Nordic stan-
dards and the International Study of Asthma and Allergies
in Childhood (ISAAC) phase II protocol. The large multi-
center GA2LEN study was carried out in 17 centers in 14
countries and showed that a proposed standard protocol
and allergen panel for SPT are feasible [3,4].
Indication for SPT
SPT is indicated if a type I (immediate type) allergy is sus-
pected, based on the medical history and clinical symp-
toms; they can identify sensitivity to inhalant, food, drug
or occupational allergens. SPTs thus provide objective
confirmation of sensitivity, whereas the relevance of such
sensitivity to allergens should always be carefully inter-
preted in the light of the clinical history so that appropri-
ate advice concerning avoidance measures can be given
and, as necessary, the correct allergen(s) prescribed for
specific immunotherapy (SIT). SPT results correlate with
those of nasal challenge which may also be used as a
surrogate to test clinically relevant sensitization [5].Another indication of SPT is to screen for a predispos-
ition to develop atopic diseases, which can be done with
a limited number of allergens, or to identify all sensitized
subjects in a given population. SPT also can be used in
epidemiologic studies to determine trends in sensitization
rates or regional differences and to help standardize aller-
gen extracts.
SPT is used to test adults and children from birth on-
wards. Repeated testing may be necessary in order to de-
tect new sensitizations, especially in children, when
symptoms change, or if new environmental allergens are
suspected.
General principle in SPT
SPT interpretation utilizes the presence and degree of cu-
taneous reactivity as a surrogate marker for sensitization
within target organs, i.e., eyes, nose, lung, gut and skin.
When relevant allergens are introduced into the skin, spe-
cific IgE bound to the surface receptors on mast cells are
cross-linked, mast cells degranulate, and histamine and
other mediators are released. This produces a wheal and
flare response which can be quantitated. Many different
allergens can be tested simultaneously because the result-
ant reaction to a specific allergen is localized to the imme-
diate area of the SPT.
Comparison with other methods
The chief advantage of SPT as compared to an in vitro
measurement of specific IgE antibodies is that the test
can be interpreted within 15 to 20 minutes after the re-
agent is applied to the skin. Moreover, the test gives a
visual indication of the sensitivity which can be used in
order to impact the patient’s behavior. SPT can also be
utilized to test less common allergens, such as certain
medications, and fresh fruits and vegetables where no
specific IgE antibody measurements are available.
The skin scratch test, first described by Blackley in
1873 [6], is not recommended as a test modality for in-
halant or food allergens since results are more difficult
to interpret and standardize. Scratch testing may result
in varying quantities of allergen absorbed, mechanical ir-
ritation of the skin [7] , bleeding at the test site, and
carries a higher risk of inducing a systemic allergic
reaction.
The in vitro measurement of specific IgE antibodies
[8-10] is an important complementary tool to diagnose
type I allergy, especially in subjects who cannot undergo
SPT. For example, SPT is not practical in patients who
have extensive eczema, dermographism, urticaria, or
who are taking antihistamines or other medications
which interfere with the proper interpretation of the test
results (Table 2). In vitro test methods may be less sensi-
tive [11,12] and/or less specific [13,14] than SPT de-
pending on the method utilized and the allergens
Table 2 Potential interference of medications with the skin test reaction (adapted from Demoly (2003) [23];
Rueff (2010) [24] and Position Paper: Allergen standardization and skin tests: The European Academy of Allergy (1993))
Drug Suppression Abstinence before testing Reference
0: no evidence; (+): possible,
+: slight; ++: medium,
+++: strong
Antihistamines
1st generation H1-blocker +++ > 2 days Dreborg (1989) [25]
Hydroxyzine
2nd generation H1-blocker +++ 7 days Devillier (2008) [26]
Cetirizine, Loratadine, etc.
Ketotifen +++ > 5 days
H2-blocker 0 - + Ø
Glucocorticosteroids
Topical (in test area) + > 1 week 1 Hammarlund (1990) [27],
Pipkorn (1989) [28],
Gradman (2008) [29]
Nasal 0 Ø
Inhaled 0 Ø
Systemic/short term (up to 10 days) 0 / (+)
< 50 mg/d Prednisolone-equivalent 0 / (+) > 3 days Hammarlund (1990) [30]
> 50 mg/d Prednisolone-equivalent (+) > 1 week 2 Des Roches (1996) [31]
Systemic/long term (more than 10
days)
<10 mg/d Prednisolone-equivalent 0 Ø Olson (1990) [32]
>10 mg/d Prednisolone-equivalent 0 > 3 weeks 2 Des Roches (1996) [31]
Topical calcineurin inhibitors + > 1 week Gradman (2008) [29]
Other systemic drugs
Omalizumab ++ > 4 weeks Noga (2003) [33]
Leukotriene receptor antagonist 0 Ø Cuhadaroglu (2001) [34], Hill (2003) [35]
Cyclosporin A 0 Ø Munro (1991) [36]
Theophylline 0 Ø Spector (1979) [37]
Antidepressants
Doxepin ++ 7 days Rao (1988) [38]
Desipramine ++ 3 days Rao (1988) [38]
SSRI: Citalopram, Fluoxetin, Sertralin 0 Ø Isik (2011) [39]
β-adrenergic agonists 0 Ø Abramowitz (1980) [40], Spector (1979) [39]
Salbutamol, Salmeterol, Bambuterol,
Terbutalin
0 Petersen (2003) [41]
1 Depends on dosage and length of treatment (> 3 weeks).
2 A retrospective study showed no influence of the skin reaction by 10–60 mg prednisone for 2 or more years.
Heinzerling et al. Clinical and Translational Allergy 2013, 3:3 Page 3 of 10
http://www.ctajournal.com/content/3/1/3employed. Furthermore, in subjects with very high total
serum IgE antibodies, low levels of specific IgE anti-
bodies of doubtful clinical relevance are often detected.
Concordance between in vitro specific IgE antibody
assays and SPT results is between 85% and 95%, depend-
ing on the allergen being tested [15-18] and the methodused to detect specific IgE [19-21]. In a study of over
8000 subjects, SPT versus quantitation of specific IgE
antibodies, for example, with the CAP FEIA technology
(PhadiatopW, Pharmacia, Uppsala, Sweden), had the best
positive predictive value to determine clinical allergy for
respiratory allergic diseases [22]. Moreover, SPT provides
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may not be available for days or weeks. Thus, SPT has
greater flexibility and is usually less costly.
Intradermal skin tests are more sensitive but less spe-
cific than SPT [42]. They are more labor-intensive and
require more precise techniques. These tests have occa-
sionally been associated with serious systemic allergic
reactions and even death from anaphylaxis [43,44]. In
clinical practice, SPT tests should always be performed
first since a positive test circumvents the necessity for
intradermal skin testing. Extracts utilized for intradermal
skin testing are less concentrated (1:10–1:1000; 0.00001
μg/ml up to 1 μg/ml [42,45]) than those utilized for SPT
and should be free of glycerine, in order to avoid false-
positive reactions. In the diagnosis of pollen allergy, sev-
eral studies indicate that positive intradermal skin tests
do not necessarily correlate with clinical symptoms
[22,42] whereas there is a very good correlation between
SPT results and clinical allergy symptoms [25]. Thus, for
the most part, SPT is preferable to intradermal testing,
the latter being primarily used for Hymenoptera venom
sensitivity, sensitization to medications, and where an
allergen is considered historically relevant and in the
circumstance that the SPT is negative [46]. Titration
tests for Hymenoptera venoms are usually begun at
concentrations of 1:1000 or after prior negative SPT
using 1:100.
Performance of the skin prick test
Preparation, precautions and contraindications
SPT is safe with no reported fatalities in a 5-year USA
study [47]. Because systemic allergic reactions and rare
deaths have occurred associated with SPT [44,48], a
physician or other health care professional and emer-
gency equipment should be immediately available when
such tests are performed. This is especially true when
testing for a food or medication associated with the
onset of anaphylaxis [49]. Systemic side effects are very
unlikely for commercially available respiratory allergens
[50]. Symptomatic asthma may be a risk factor for ex-
acerbation of asthma associated with testing [44]. When
reactions occur, they usually do so within 30 minutes of
testing [50]. Measurement of specific IgE antibodies or
titrated SPT are sometimes desirable for patients with
severe anaphylaxis suspected from a specific allergen to
which they are being tested, i.e., peanuts, tree nuts and
shellfish. SPT should be performed with extra caution
during the respective allergy season when the patient
has allergic symptoms, or when baseline tryptase levels
are elevated. The latter is a risk factor for anaphylaxis
[51]. Likewise, patients, especially those taking a beta
blocker, or less often, angiotensin converting enzyme
(ACE)-inhibitor, may be at a higher risk because of less
response to epinephrine that might be needed to treat asystemic allergic reaction. Relative contraindications for
SPT include pregnancy, in view of a remote possibility
of inducing a systemic allergic reaction that could induce
uterine contractions or necessitate the use of epineph-
rine (thought to cause constriction of the umbilical
artery [52]). SPTs are difficult to perform in patients
with severe eczema, dermographism, or who are taking
antihistamines or other medications such as certain anti-
depressants or calcineurin inhibitors (see Table 2) which
can interfere with the proper interpretation of the test
results. In vitro testing is recommended in these cases.
The degree of skin test reactivity can be decreased in
subjects with chronic illnesses such as renal failure, or
cancer. Furthermore, chronic or acute UV-B radiation of
the skin in the test area may reduce the wheal size from
SPT [53].
The stability and expiration date of the allergen
extracts utilized should always be checked. Test extracts
should be stored at +2°C - +8°C when not utilized to
maintain stability. Histamine dihydrochloride (10 mg/ml
or 0.1%) can be used as a positive control and diluent,
as used in the test extracts, as a negative control. For
oral allergy syndrome induced by certain foods, raw
foods, i.e., fresh fruits and vegetables are preferably used.
The skin of the fruit or vegetable is pricked and then the
skin of the allergic patient, in order to determine skin
test reactivity.
SPT procedure
Patients should be appropriately screened for asthma,
and, where possible, discontinued on medications that
interfere with test results, accentuate systemic allergic
reactions or render patients less responsive to treatment
with epinephrine. In patients with a history of severe
systemic allergic reactions to food or drugs, an intraven-
ous line for immediate circulatory access can be recom-
mended. A peak flow of less than 70% in patients with
asthma is a relative contraindication. Asthma should be
controlled or testing deferred until control is achieved.
When testing patients with a history of a severe systemic
allergic reactions, skin test titration, first utilizing diluted
extracts, is recommended. SPT should ideally be per-
formed at least 4–6 weeks following a systemic allergic
reaction, in particular, for Hymenoptera hypersensitivity,
since test reactivity may be falsely negative for weeks fol-
lowing such a reaction [24,54].
The location of each allergen can be marked with a
pen or by using a test grid on the forearm to properly
identify test results (Figure 1a). Tests should be applied
to the volar aspect of the forearm, at least 2 – 3 cm from
the wrist and the antecubital fossae [52]. The back can
also be used for SPT, especially in infants. The skin on
the back is more sensitive than the forearm which may
result in larger wheals and thus possibly a greater
Figure 1 SPT procedures. (a) Preparation for skin prick test on forearm. (b) Prick testing with lancet through a drop of allergen extract.
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tween two skin prick tests (≥ 2 cm) is critical to avoid
false-positive reactions due to direct contamination of a
nearby test or secondary to an axon reflex [55]. A drop
of each test solution should be placed on the skin in
identical order for each subject tested and immediately
pricked.
A single-head metal lancet exhibits excellent reprodu-
cibility with few false-negative results and is thus the
preferred testing instrument for SPT [56-58]. It is
pressed through the drop of allergen extract and held
against the skin for at least 1 second (Figure 1b), with
equal pressure applied for each test. The epithelial layer
of the skin should be penetrated without inducing bleed-
ing, which can lead to false-positive results. A new lan-
cet should be utilized for each allergen since wiping a
previously used one between tests could result in cross-
contamination from the previous allergen tested [59].
Wiping lancets also represents a potential risk factor for
the healthcare professional performing the test. Excess
solution from drops on the skin can be blotted using a
clean tissue. It is important to assure that there is no
cross-contamination between drops of different allergen
extracts, i.e., that the drops do not run together. A timer,
with an alarm, should be utilized so that all tests, includ-
ing the histamine and negative control test results are
read 15–20 minutes following application. Such timing
for test results is recommended even though the hista-
mine control can peak earlier at approximately 8–10
minutes [60].
It is difficult or impossible to develop stable test
extracts for certain allergens, in particular, certain foods,
e.g., for skin testing to uncooked fruits and vegetables. A
prick-to-prick technique is utilized, i.e., first pricking the
fresh food with the lancet and then pricking the skin, to
test for sensitization to such allergens when clinical allergy
is suspected, in particular, oral allergy syndrome. Dryfoods, e.g., nuts or cereal, can be pestled in saline and also
utilized using the prick-to-prick technique. There can be
differences in the degree of skin test reactivity depending
on the variety of a fruit or vegetable, how ripe it is, and
how it has been stored prior to its use [61].Assessing the SPT
Positive and negative controls should be measured first.
The negative control excludes the presence of dermo-
graphism which, when present, makes the tests difficult
to interpret. The histamine control should be positive to
make sure that the test materials are applied correctly
and to exclude negative SPT results due to potentially
interfering medications taken by the test subject
(Table 2). The largest diameter of the wheal of each
particular test is measured, a positive being a wheal
of ≥ 3 mm [62] since the longest diameter is a better
estimate of wheal surface area than the mean perpen-
dicular diameters of a skin prick test above a certain
value (17 mm2). The negative control is no longer used
to deduct its size from the positive tests. Including the
longest diameter of pseudopods does not increase sen-
sitivity for determining the degree of sensitisation.
Since histamine reactivity in the skin varies among indi-
viduals, independent of skin test reactivity to allergens [52],
the skin test results to allergens should not be related to
the size of the histamine reaction [63]. The size of the
wheal is not solely due to histamine as some subjects with
positive SPT reaction show no significant histamine release
to these allergens as assessed by microdialysis technique
[64]. Reproducibility is greater when only the diameter of
the wheal, and not the associated erythema, is measured
[65,66]. In order to achieve a permanent record, the size of
the wheal may be outlined with a pen, blotted onto a cello-
phane tape, and transcribed onto paper and/or stored
electronically.
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The SPT confirms sensitization to a specific allergen, how-
ever, its clinical relevance must be interpreted based on
the medical history and clinical symptoms (see Additional
file 1: Table S3). Sometimes, conjunctival, intranasal, oral
or even bronchial challenge provocation tests are per-
formed to support clinically relevant sensitivity. The clin-
ical relevance of SPT results varies, depending on the
allergen utilized and the population tested. For example,
sensitization to house dust mite occurs in some subjects
in the absence of clinical relevance [4].
Extracts
Allergen extracts ideally should be standardized based
on the content of the major and minor allergenic deter-
minants since not all patients are allergic to each antigen
within an individual extract. They should have batch-to-
batch consistency and the skin test results should be
comparable when the same extracts from different man-
ufacturers are utilized. Since allergen extracts are bio-
logical mixtures containing a variety of different proteins,
glycoproteins and polysaccharides, this is difficult to
achieve. In fact, SPT results obtained with the same al-
lergen with extracts from different manufacturers vary
[67-72]. Thus, when SPT results are compared, the al-
lergen extract utilized should be obtained from the
same manufacturer. Likewise, effective allergen im-
munotherapy requires specified quantities of allergenic
components in the extracts used for immunotherapy.
The fact that accurate standardization of extracts is of
great importance for their quality has led manufacturers
to implement extensive protocols for standardization.
Each company uses its own in-house reference material
and unique units to express potencies. Such variability
among different manufacturers leads to an inability to
compare different products and test results. However,
since most major allergens of relevant allergens have
been identified during the last several decades, the con-
cept introduced is to quantitate the major allergens in
each of the individual extracts. Such quantification will
allow comparison between products by different manu-
facturers. In 2001, an EU funded project, the CREATE
project, was introduced to encourage standardisation of
allergen extracts based on their content of major aller-
gen(s). The project evaluated the use of recombinant
allergens as reference materials for major allergen mea-
surements [73]. Another attempt to standardize extracts
involved the development of recombinant allergen
extracts. Even though some of these recombinant aller-
gens show comparability to allergen extracts derived
from source material [74-76], they only cover a limited
number of allergens and are still under investigation.
Extracts should not contain preservatives which can
cause false positive reactions, e.g., sodium merthiolate.Nor should they be mixed with other allergens, e.g.
house dust mite with dog dander extract. When testing
with non-commercial allergens, there is a real need to
use control tests in non-allergic subjects to compare the
results with subjects who are allergic. For certain plant
allergens, especially for fresh foods and vegetables, the
prick-to-prick method is more reliable than using manu-
factured extracts [61].
The tight regulation of skin test extracts has made
their production and registration problematic and costly
for the pharmaceutical industry. This has led to gaps in
the registration of specific extracts in certain European
countries.Pan-European skin prick test panel for respiratory
allergens
The authors suggest that a standard SPT panel for inhalant
allergens, based on the GA2LEN study [3], be utilized
throughout Europe. This panel includes the following 18
allergens: hazel (Corylus avellana), alder (Alnus incana),
birch (Betula alba), plane (Platanus vulgaris), cypress
(Cupressus sempervirens), grass mix (smooth meadow
grass/Poa pratensis, cock’s foot grass/Dactilis glomerata,
perennial rye grass/Lolium perenne, timothy grass/Phleum
pratense, meadow fescue/Festuca pratensis, meadow oat
grass/Helictotrichon pretense), Olive (Olea europaea), mug-
wort (Artemisia vulgaris), ragweed (Ambrosia artemisiifo-
lia), Alternaria alternata (tenuis), Cladosporium herbarum,
Aspergillus fumigatus, Parietaria, cat, dog, Dermatopha-
goides pteronyssinus, Dermatophagoides farinae, and cock-
roach (Blatella germanica). Allergens can be supplemented
as necessary for regional or for particular patient needs.Interpretation of SPT results
SPT results should be appropriately interpreted based
on clinical symptoms, medical history, and, where neces-
sary, other test results (specific IgE antibody measure-
ments) in order to assess possible allergy to a specific
allergen. The probability of a given sensitization to be
clinically relevant depends on the type of allergen and
country where the patient lives [4]. The clinical rele-
vance of any detected sensitization should be determined
by an allergologist after taking a complete history and per-
forming a physical examination. When SPT results and
the history are inconclusive, provocation tests may help to
determine the clinical relevance of the SPT sensitization,
e.g., before initiation of a specific immunotherapy.
SPT is highly specific and sensitive, 70-95% and 80-97%,
respectively, to diagnose inhalant allergies [76]. The posi-
tive predictive value to diagnose allergic rhinitis based
only on the clinical history is 77% for persistent allergy
and 82-85% for intermittent seasonal allergy [17]. This
increases to 97-99% if SPT is utilized [17].
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in vitro IgE antibody test for cat allergen are identical at
72-75% for cat allergy [42]. A negative SPT for Dermato-
phagoides pteronyssinus has a negative predictive value
in older adults of 90%-95%. However, the positive pre-
dictive value ranges from 29% to 43% in older subjects
and 77% to 100% for younger subjects [23].
Sensitivity and specificity are lower for food allergens,
ranging from 30-90% and 20-60%, depending on the
type of allergen and methods utilized, i.e. pricking with
extracts vs. prick-to-prick techniques described earlier
[77]. Double-blind placebo-controlled challenge studies
in children demonstrate that SPT possesses a positive
predictive value of 76% and 89% for clinical reactions to
cow’s milk and hen’s egg, respectively [78].
The objective value of SPT for drug allergy depends
on the tested drug. In most cases, a positive SPT makes
drug allergy very probable; whereas a negative result
does not necessarily indicate that the patient will not
react on challenge to the drug [79]. However, for penicil-
lin, the negative predictive value is high. In 98.5% of
patients with a negative SPT, no type I allergy was
observed upon challenge while the remaining 1.5% of
patients had mild and self-limiting reactions, e.g., urti-
caria [80]. In many cases, intradermal testing is appro-
priate after negative SPT. Some drugs, e.g., muscle
relaxants or opioids may cause SPT false-positive results.
When evaluating patients for IgE-mediated drug allergy
to antibiotics other than penicillin, SPT should be per-
formed with the unadulterated pharmaceutical agent.
Late readings (> 24h) of SPTs and especially intradermal
skin tests are very valuable in the clarification of adverse
drug reactions.
For suspected insect venom allergy, intradermal tests
are the primary mode for detecting sensitization. SPT is
performed prior to intradermal testing.
Sensitizations to aeroallergens, as measured by SPT,
may precede symptomatic allergy. Prospective studies
show that 30-60% of such subjects become allergic de-
pending on the type of allergen tested and the time to
follow-up [81,82]. Furthermore, sensitization can exist to
an allergen that is no longer clinically relevant.
SPT in epidemiologic studies
Sensitization rates vary depending on the geographic
region as measured in population-based and in patient-
based studies like the European Community Respiratory
Health Survey (ECHRS), the International Study of
Asthma and Allergies in Childhood (ISAAC), and the
GA2LEN Pan-European skin prick test study. Exposure
rates and genetic differences can explain some of these
variations [83,84]. With increased human mobility, dif-
ferences in exposure to various flora or alterations in the
allergenicity of pollen, possibly caused by pollution[85,86], and changes in sensitization occur over time
[87]. Longitudinal studies investigating sensitization over
time provide data on such trends [88,89].
The same allergen extracts and ideally even the same
batches of extracts should be utilized when comparing a
test result from one place to another or over time. For
epidemiological studies, the standard prick test panel
should be utilized to ensure comparability with the
GA2LEN study results (see Table 1; [3]). Distribution of
standard operating procedures for both technical aspects
and data collection assures the highest degree of com-
parability. Studies of allergic sensitization should take
place over an extended period of time, ideally, a year,
since (i) skin test reactivity increases during the pollen
season [90] and (ii) allergic individuals tend to seek care
when they have symptoms. This can skew detected
prevalence of sensitization in such studies. It is also im-
portant to note the seasonal differences of various aller-
gens based on geographic locations which can further
distort sensitization rates between countries.
Future directions to use skin tests for allergy
diagnosis
More than 1,800 allergenic molecules are identified
(http://www.allergome.org/script/statistic.php; [91]). The
use of recombinant allergen molecules for SPT should
improve sensitivity and standardization of SPT by redu-
cing non-specific reactivity due to irritant compounds
contained in biologically derived extracts, in particular,
food extracts [92]. New in vitro techniques using recom-
binant molecules and micro-technology may permit test-
ing of hundreds of compounds simultaneously, thus
improving diagnostic possibilities and potentially even
eliminating the need for skin testing [93].
Needs for further research
Further studies are needed to (1) compare extracts from
different manufacturers, (2) investigate intra subject
variability, and (3) determine the relevance of SPT for
pan-allergens. Since new allergens are being identified
in Europe, e.g., acerola (Malpighia glabra), and others
are becoming more prevalent, e.g., Lepidoglyphus de-
structor, new studies should also investigate the rele-
vance of these allergens.
Conclusion and outlook
There is general agreement that the core diagnostic test
for type I immediate allergy, i.e. the SPT, should be fur-
ther standardized to include standardized procedures
and allergen panels. Additional allergens can be added
to this “core”, when indicated. Such standards are likely
to: (1) improve the quality of patient diagnosis and care,
and (2) reduce variability of results and thus make test
Heinzerling et al. Clinical and Translational Allergy 2013, 3:3 Page 8 of 10
http://www.ctajournal.com/content/3/1/3results comparable. Further studies are necessary to
define worldwide standards for allergen extracts.
Additional file
Additional file 1: Table S3. Skin prick test panel – inhalant allergens.
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